Trials / Terminated
TerminatedNCT00607399
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, Ona Twice Daily, Interrupted Schedule in Patients With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- SGX Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGX523 Capsules | This is a dose escalation study |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-01-01
- Completion
- 2009-06-01
- First posted
- 2008-02-05
- Last updated
- 2008-07-24
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00607399. Inclusion in this directory is not an endorsement.